Document Type

Article

Publication Date

5-2020

Identifier

DOI: 10.1111/cts.12749; PMCID: PMC7214659

Abstract

This study investigated the impact of SLCO1B1 genotype on rosuvastatin systemic exposure in hypercholesterolemic children and adolescents. Participants (8-21 years) with at least one allelic variant of SLCO1B1 c.521T>C (521TC, n = 13; 521CC, n = 2) and wild type controls (521TT, n = 13) completed a single oral dose pharmacokinetic study. The variability contributed by SLCO1B1 c.521 sequence variation to rosuvastatin (RVA) systemic exposure among our pediatric cohort was comparable to previous studies in adults. RVA concentration-time curve from 0-24 hours (AUC

Journal Title

Clin Transl Sci

Volume

13

Issue

3

First Page

628

Last Page

637

Share

COinS